Mobile website
Basic Research
CH12 monoclonal antibody inhibits growth of head and neck squamous cell carcinomas xenografts in nude mice
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the inhibitory effect of chimeric monoclonal antibody CH12 on the growth of head and neck squamous cell carcinoma (HNSCC) xenografts in vivo, and to provide basis for further study on the effect CH12 antibody on tumor therapy. Methods: The protein expression levels of the epidermal growth factor receptor (EGFR) in A253, CAL27, Detroit 562, FaDu and RPMI 2650 HNSCC cell lines were analyzed by Western blotting. The binding capacity of CH12 antibody with these five cell lines was detected by flow cytometry. CAL27 and A253 cells were subcutaneously inoculated into nude mice to establish HNSCC xenograft models. The mice with xenografted tumor were randomized into two groups: a ehicle control group (PBS) and a treatment group (CH12). Tumor volume was recorded at a regular time interval, and then the tumor growth curve was drawn. Results: EGFR was expressed in CAL27, A253,FaDu and Detroit 562 cell lines, with the highest expression in CAL27 cells and the second highest expression in A253 cells.The binding affinity of CH12 with five cell lines was followed by CAL27, FaDu, A253, Detroit 562 and RPMI 265. CH12 significantly inhibited the tumor growth in both CAL27 and A253 xenografts compared with that in the control group, and the tumor growth inhibition ratios were 56.8% (P=0.022) and 59.7% (P=0.015) respectively. Conclusion: CH12 antibody can effectively inhibit the tumor growth of EGFR high-expressed HNSCC xenografts in vivo.
Keywords:
Project Supported:
Project supported by the Key Program Project of the Shanghai Science and Technology Committee (No. 10431903700), and the Doctoral Program Foundation of Institutions of Higher Education of China (No. 20090073120109).
Clc Number:
